| Business Summary | | Angiotech
Pharmaceuticals
is
a
Canadian
pharmaceutical
company
dedicated
to
the
development
of
medical
device
coatings
and
treatments
for
chronic
inflammatory
diseases
through
reformulation
of
the
anticancer
drug,
paclitaxel.
These
treatments
are
based
upon
the
Company's
discovery
that
paclitaxel,
one
of
the
most
commercially
successful
and
clinically
effective
anticancer
drugs
ever
produced,
also
blocks
an
important
cellular
pathway
involved
in
inflammation. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | Angiotech
Pharmaceuticals
is
a
Pharmaceutical
company
engaged
in
the
development
of
medical
device
coatings
and
treatments
for
chronic
inflammatory
diseases
through
reformulation
of
the
anticancer
drug
Paclitaxel.
For
the
nine
months
ended
6/30/01,
revenues
fell
from
C$4.5
million
to
C$0.
Net
loss
rose
from
C$2.4
million
to
C$8.4
million.
Revenues
reflect
the
absence
of
license
and
contract
research
fees.
Higher
loss
reflects
higher
R&D,
administrative
and
amortization
costs. | More
from
Market Guide: Significant
Developments |
| Officers | |
| Position | William Hunter, M.D. | Chairman,
CEO | Donald Longenecker, Ph.D. | Pres,
COO, Director | David Hall | Sr.
VP-Fin. | David Hartnett | Sr.
VP, Operations | David McMasters | VP,
Intellectual Property, Gen. Counsel |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|